...
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Quantitative real-time rt-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients.
【24h】

Quantitative real-time rt-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients.

机译:使用序列特异性寡核苷酸杂交探针在前列腺癌患者中定量实时rt-PCR检测循环中的前列腺特异性抗原mRNA。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: A great number of studies have failed thus far to demonstrate that the presence of PSA-expressing tumor cells in the blood of prostate cancer (PC) patients is a highly sensitive prognostic marker, particularly after radical prostatectomy (RPX). These studies have only relied on qualitative or semiquantitative detection techniques, however. We report our initial experience in testing real-time RT-PCR for the detection of PSA mRNA using a quantitative online PCR system, the LightCycler(TM), and sequence-specific oligonucleotide hybridization probes. METHODS: Blood samples were obtained before and after surgery from 129 patients undergoing RPX for localized PC and from 19 patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia (BPH). Quantitative RT-PCR for the detection PSA mRNA was performed using the LightCycler system with RNA Amplification Kit Hybridization Probes and sequence-specific oligonucleotide hybridization probes. RESULTS: PSA mRNA was detectedby the LightCycler in 28 patients (39%) with pT2 tumors, in 22 patients (38%) with >pT2 tumors, but in only 3 patients (16%) with BPH. The mean values of the LNCaP cell equivalents were higher in >pT2 patients than in pT2 patients (37 x 10(3) and 104 x 10(3)) or BPH patients (7.1 x 10(3) and 4.8 x 10(3)) both preoperatively (333 x 10(3)/ml blood) and postoperatively (545 x 10(3)). CONCLUSION: Real-time RT-PCR with the LightCycler appears to be a promising method for the preoperative detection of circulating LNCaP tumor cells in PC as reflected by PSA mRNA. Considering the low detection rates in BPH patients, the method may also be suitable for patient monitoring after RPX and could thus play an important role in deciding on early radiotherapy or even hormone ablation therapy. Additional long-term follow-up will have to show whether patients with high expression of PSA mRNA actually have an increased risk or recurrence and whether the method is suitable as well to detect progression.
机译:目的:迄今为止,大量研究未能证明前列腺癌(PC)患者血液中存在表达PSA的肿瘤细胞是高度敏感的预后标志物,尤其是在根治性前列腺切除术(RPX)后。但是,这些研究仅依赖于定性或半定量检测技术。我们报告了使用定量在线PCR系统,LightCycler(TM)和序列特异性寡核苷酸杂交探针测试实时RT-PCR以检测PSA mRNA的初步经验。方法:在手术前后分别从129例接受RPX进行局部PC手术的患者和19例经尿道前列腺电切术进行良性前列腺增生(BPH)的患者中获取血液样本。使用具有RNA扩增试剂盒杂交探针和序列特异性寡核苷酸杂交探针的LightCycler系统进行定量PSA mRNA的定量RT-PCR。结果:LightCycler在28例pT2肿瘤患者中检出PSA mRNA(39%),在22例> pT2肿瘤患者中检出PSA mRNA(38%),但仅3例BPH患者(16%)检出。 > pT2患者的LNCaP细胞当量平均值高于pT2患者(37 x 10(3)和104 x 10(3))或BPH患者(7.1 x 10(3)和4.8 x 10(3) ),无论是术前(333 x 10(3)/ ml血液)还是术后(545 x 10(3))。结论:通过PSA mRNA反映,采用LightCycler实时RT-PCR似乎是一种有前途的方法,可用于术前检测PC机中循环LNCaP肿瘤细胞。考虑到BPH患者的低检出率,该方法也可能适用于RPX后的患者监测,因此在决定早期放疗甚至激素消融治疗中起着重要作用。额外的长期随访将必须显示PSA mRNA高表达的患者是否确实具有增加的风险或复发,以及该方法是否也适合检测进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号